Last updated on March 2020

A Study Evaluating the Efficacy of the Combination of Hypofractionated Stereotactic Radiation Therapy With the Anti-PDL1 Immune Checkpoint Inhibitor Durvalumab in NSCLC Patients With 1 to 4 Brain Metastases

Brief description of study

This study is a phase II, multicenter, randomized and comparative study designed to evaluate whether the combination of hypofractionated stereotactic radiation therapy with the anti-PD-L1 Durvalumab in patients with brain metastases from NSCLC (Non-Small-Cell Lung Carcinoma) improves brain tumor control compared to hypofractionated stereotactic radiation therapy alone.

Patients will be assigned in one of the two following arms:

  • Arm A (control arm): radiotherapy alone
  • Arm B (Experimental arm): combined treatment radiotherapy with anti-PD-L1 durvalumab

Total duration of treatment will be 12 months (at maximum in the experimental arm).

Patients will be followed for a maximum of 2 years following the date of randomization.

Clinical Study Identifier: NCT03955198

Find a site near you

Start Over